Hoffmann, V S
Baccarani, M
Hasford, J
Castagnetti, F
Di Raimondo, F
Casado, L F
Turkina, A
Zackova, D
Ossenkoppele, G
Zaritskey, A
Höglund, M
Simonsson, B
Indrak, K
Sninska, Z
Sacha, T
Clark, R
Bogdanovic, A
Hellmann, A
Griskevicius, L
Schubert-Fritschle, G
Sertic, D
Guilhot, J
Lejniece, S
Zupan, I
Burgstaller, S
Koskenvesa, P
Everaus, H
Costeas, P
Lindoerfer, D
Rosti, G
Saussele, S
Hochhaus, A
Hehlmann, R
Article History
Received: 4 May 2016
Revised: 22 July 2016
Accepted: 15 August 2016
First Online: 29 August 2016
Competing interests
: VSH, MB, and JH receive research funding from Novartis. FC has a consulting role and receives honoraria from Novartis, BMS, ARIAD and Pfizer. FR receives honoraria from BMS and has a consulting role at Novartis. LFC has a consulting role and receives funding for clinical research from Novartis, BMS and Pfizer. AT has a consulting role at Novartis, BMS and Pfizer. DZ receives funding of travel, accommodations or expenses from Novartis and BMS. AZ has a consulting or advisory role at and participated in a speakers’ bureau for Novartis and received research funding from BMS. BS has a consulting or advisory role at BMS. ZS has a consulting or advisory role at Novartis. TS has a consulting role at Novartis, BMS, Adamed and Angelini. RC has had research funding from Novartis, Bristol-Myers-Squibb and Pfizer, and has been on the speakers bureau of Novartis and Pfizer in the past 5 years. AB has participated in a speakers’ bureau and received research support from Novartis Pharma Services/Office in Serbia via the patient assistant support program. AH participated in a speakers’ bureau for Novartis and BMS, receives research funding and funding of travel, accommodations or expenses from Novartis and BMS, and provides expert testimony for Novartis and BMS. LG receives research grants from Novartis. SB receives honoraria from Novartis, Celgene and AOP, has a consulting or advisory role at Novartis and Celgene and receives funding of travel, accommodations or expenses from Novartis and AOP. PK has a consulting or advisory role at GSK, BMS and Novartis, receives funding from Novartis, provides expert testimony for Pfizer and Novartis and receives funding of travel, accommodations or expenses from BMS and Ariad. DL receives research funding from Novartis. SS has received research support from Novartis and BMS and receives honoraria from Novartis, BMS, Ariad and Pfizer. AH has received research funding from Novartis. RH has received research support from Novartis, Consultant for BMS. KI, GSF, DS, JG, SL, IZ, HE, PC, GO and GR have no conflict of financial interests to declare.